Verastem Inc. (NASDAQ: VSTM) is a clinical stage biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem's product candidates seek to treat cancer by targeting malignant cells both directly and through modulation of the tumor microenvironment. Our most advanced programs target the phosphoinositide-3-kinase (PI3K) and Focal Adhesion Kinase (FAK) pathways.
March 23, 2017
Verastem Reports Year-End 2016 Financial Results
March 16, 2017
Verastem to Host Conference Call on March 23rd to Discuss Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights
March 15, 2017
Verastem to Present at the Oppenheimer 27th Annual Healthcare Conference
Major advances in cancer treatment have led to significant improvements in efficacy. However, this benefit does not extend to all patients. Challenges in the tumor microenvironment may both support tumor survival, and inhibit anti-tumor activity of cancer therapies and adaptive immune response.